Standard mammography (film or digital) is currently the most common method of screening women for breast cancer.
The conclusions of the group, convened by the International Agency for Research on Cancer (IARC), are published in the New England Journal of Medicine and come following new data on screening practices and their outcomes.
"Careful consideration of both the benefits and harms of mammography screening shows a net benefit from inviting women 50-69 years old," says Dr. Béatrice Lauby-Secretan, an IARC scientist. "The significant reduction in breast cancer mortality observed in this age group outweighs the effects of overdiagnosis and other adverse effects."
According to the IARC, breast cancer is the most frequently diagnosed cause of death from cancer in women worldwide. In low- and middle-income countries, it is the leading cause of death from cancer for women and the second leading cause of death from cancer for women in developed countries.
Standard mammography is currently the most common means of screening women for breast cancer, available through either organized programs or opportunistic screening for individuals on request as part of routine health check-ups.
The IARC previously stated in 2002 that evidence for the efficacy of using mammography as the sole means of screening in reducing mortality from breast cancer "was sufficient for women 50 to 69 years of age, limited for women 40 to 49 years of age, and inadequate for women younger than 40 or older than 69 years of age."
In light of research that has been conducted in subsequent years and improved outcomes for late-stage breast cancer, the IARC decided that an update of their findings was required, and so set about reviewing all published peer-reviewed scientific literature in the field, including data for emerging technologies, clinical breast examination and breast self-examination.
Benefits of mammography deemed to outweigh adverse effects
Following their review, the experts conclude that mammography screening is effective in reducing breast cancer mortality in women aged 50-69 and continued to be beneficial to women aged 70-74.
In particular, data obtained from around 20 cohort and 20 case-control studies conducted in high-income countries indicate that women aged 50-69 who underwent mammography screening had a breast cancer mortality around 40% lower than those who did not attend mammography screening.
However, evidence indicating the efficacy of mammography screening among women aged 40-49 is considered by the group to be limited.
The group notes that there are a number of adverse effects associated with mammography. False-positive results can have short-term negative psychological consequences and lead to unnecessary treatment, and there is an increased risk of radiation-induced breast cancer from screening in women aged 50 and above.
Despite these adverse effects, the group concludes that these risks are substantially outweighed by the overall reduction in breast cancer mortality associated with screening. The group also found that mammography screening was capable of detecting breast cancers that would have caused harm or never have been diagnosed had the women not been screened.
Alternative methods of screening to mammography have been investigated by researchers, but the group could not find sufficient evidence for a reduction in breast cancer mortality associated with these emerging technologies. Similarly, most studies did not indicate a reduction in breast cancer mortality caused by breast self-examination.
The assessments will also be published as IARC Handbook of Cancer Prevention Volume 15.
"The IARC Handbook on breast cancer screening provides the most up-to-date and extensive evaluation of the scientific evidence," states Dr. Christopher Wild, director of IARC. "This provides a foundation on the basis of which governments and stakeholders can implement the best intervention strategies in order to save more lives."
Recently, Medical News Today reported on a study that suggests many women with dense breasts do not need to have additional imaging carried out for breast cancer after having a normal mammogram.